Mark Belkin

Dr. Mark Belkin


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MBMark Belkin
Mark Belkin
VKViktoriya Kagan
Viktoriya Kagan
CLColleen Labuhn
Colleen Labuhn
SPSean P. Pinney
Sean P. Pinney
JGJonathan Grinstein
Jonathan Grinstein

24 August 2023 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
JGJonathan Grinstein
Jonathan Grinstein
BHBrian A. Houston
Brian A. Houston
ANAnn B. Nguyen
Ann B. Nguyen
BSBryan A. Smith
Bryan A. Smith
ACAnnalyse Chinco
Annalyse Chinco
MBMark Belkin
Mark Belkin

25 May 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MBMark Belkin
Mark Belkin
SKSara Kalantari
Sara Kalantari
AKAnthony J. Kanelidis
Anthony J. Kanelidis
TMTamari Miller
Tamari Miller
BSBryan A. Smith
Bryan A. Smith
JGJonathan Grinstein
Jonathan Grinstein

1 July 2022 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
MBMark Belkin
Mark Belkin
JSJay Shah
Jay Shah
MNMaryam E. Neyestanak
Maryam E. Neyestanak
DBDaniel Burkhoff
Daniel Burkhoff
JGJonathan Grinstein
Jonathan Grinstein

16 November 2020 in Biomarkers
Verified
Journal Article
Closed access
NSNikhil Singh
Nikhil Singh
RARajeev K. Anchan
Rajeev K. Anchan
SBStephanie A. Besser
Stephanie A. Besser
MBMark Belkin
Mark Belkin
MCMark Dela Cruz
Mark Dela Cruz
FAFrancis J. Alenghat
Francis J. Alenghat
Background: High sensitivity troponin-T (hs-TnT) has been associated with mortality in patients hospitalized with COVID-19. We aimed to determine if hs-TnT levels and their timing are independent predictors of adverse events in these patients. Design: Retrospective chart review was performed for all patients hospitalized at our institution between March 23rd and April 13th, 2020 who were found to be COVID-19-positive. Clinical, demographic, and laboratory variables including initial and peak hs-TnT were recorded. Univariable and multivariable analyses were completed for a primary composite endpoint of in-hospital death, intubation, need for critical care, or cardiac arrest. Results: In the 276 patients analyzed, initial hs-TnT above the median (≥17ng/L) was associated with increased length of stay, need for vasoactive medications, and death, along with the composite endpoint (OR 3.92, p < 0.001). Multivariable analysis demonstrated that elevated initial hs-TnT was independently associated with the primary endpoint (OR 2.92, p = 0.01). Late-peaking hs-TnT (OR 2.19 for each additional day until peak, p < 0.001) was also independently associated with the composite endpoint. Conclusions: In patients hospitalized with COVID-19, hs-TnT identifies patients at high risk for adverse in-hospital events, and trends of hs-TnT over time, particularly during the first day, provide additional prognostic information.

1 March 2018 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
MBMark Belkin
Mark Belkin
CSCesar E. Soria
Cesar E. Soria
AWAlbert L. Waldo
Albert L. Waldo
CBC. Jan Willem Borleffs
C. Jan Willem Borleffs
DHDavid L. Hayes
David L. Hayes
GUGaurav A. Upadhyay
Gaurav A. Upadhyay
Background: Despite the clear association between atrial fibrillation and risk for thromboembolic events (TEs), the clinical significance of new-onset device-detected atrial tachyarrhythmia (DDAT) and TE remains disputed. We aimed to determine the risk of TE in patients with new-onset DDAT. Methods and Results: The OVID Medline, Cochrane, and Scopus databases (inception to November 2016) were searched. Randomized controlled trials, prospective, or retrospective studies of pacemaker or defibrillator patients reporting incidence of DDAT were selected. Summary statistics were used for analysis. Of 4893 reports identified, 28 studies following 24 984 patients were included: average age 69.9 years, 34.7% women, mean study duration 21.8±18.6 months. New-onset DDAT was observed in 23% of patients. Among 9 studies (n=8181) reporting TE, the absolute incidence was 2.1%. TE risk was significantly greater among patients with new-onset DDAT (relative risk [RR], 2.88; 95% CI, 1.79–4.64; P <0.001). TE risk was correlated with DDAT duration, with an increased risk associated with DDAT ≥5 minutes (RR, 3.86; 95% CI, 2.04–7.30; P <0.001) compared with <1 minute (RR, 1.77; 95% CI, 1.15–2.74; P =0.01). Notably, the risk of TE was also increased in patients with adjudicated atrial electrograms (RR, 3.60; 95% CI, 2.06–6.30; P <0.001) compared with nonadjudicated electrograms (RR, 2.05; 95% CI, 1.06–3.97; P =0.03), even when lower mean thresholds for detection were used. Conclusions: New-onset DDAT is common, affecting close to one quarter of all patients with implanted pacemakers or defibrillators. Adjudication of atrial electrograms further identifies at-risk patients, even when relatively short detection thresholds are used.